Q-omics provides the consensus-scored CIC profile across patient tissues and cancer cell-line models. CIC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CIC is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CIC RNA expression shows 20,455 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where CIC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CIC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CIC survival associations across molecular data types. CIC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CIC RNA expression–survival associations across cancer types. High CIC expression shows unfavorable associations in ACC, LGG, THCA and LUAD, but favorable associations in HNSC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CIC RNA expression.
This table summarizes CIC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CIC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CIC shows higher tumor expression in HNSC, LIHC, KIRC, STAD, CHOL and KIRP. The HNSC box plot shows higher CIC RNA expression in tumor versus normal tissue (log2 FC = +0.746, t-test p < 0.001).
This table shows molecular features associated with CIC in patient tissues and cancer cell lines. In patient samples, CIC shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CIC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
